Quality-of-life assessment in comparative therapeutic trials and causal structure considerations in peripheral occlusive arterial disease

被引:3
|
作者
Lehert, P
机构
[1] Univ Mons, Dept Stat, Fucam, Fac Econ, B-7000 Mons, Belgium
[2] Univ Melbourne, Fac Med, Dept Community Hlth, Melbourne, Vic, Australia
关键词
D O I
10.2165/00019053-200119020-00002
中图分类号
F [经济];
学科分类号
02 ;
摘要
When considering the use of quality of life as a primary end-point in phase III to IV comparative trials, the trial designer generally faces some unresolved questions. These include: How does one explain that some dimensions [quality-of-life (QOL) instruments usually have more than I dimension] are directly influenced by the studied treatments whereas others are not? How can one interpret conflicting results between conventional clinical measurements and QOL measurements, when the relationships between conventional clinical measurement and quality of life are not known? In this paper, we consider the use of Structural Equation Modelling (SEM) as a methodological alternative to answer these problems. As an example, we analyse the internal causal structure of the Claudication Scale (CLAU-S), a specific QOL 5-dimensional instrument for peripheral occlusive arterial disease. In applying SEM to different studies and different types of calculation, we suggest that CLAU-S is based on a stable, simple and comprehensive QOL model, is compatible with the general International Classification of Impairments, Disabilities and Handicaps (ICIDH) classification, is coherent and complementary with clinical data measurements and, using differences in a prospective study, considerably improves specificity. We suggest that SEM can help in QOL scale validation, in providing a unified scheme of the inter-relationships between internal dimensions and with external variables, in particular, clinical measurements.
引用
收藏
页码:121 / 130
页数:10
相关论文
共 50 条
  • [1] Quality-of-Life Assessment in Comparative Therapeutic Trials and Causal Structure Considerations in Peripheral Occlusive Arterial Disease
    Philippe Lehert
    PharmacoEconomics, 2001, 19 : 121 - 130
  • [2] Assessment of the quality-of-life implications of peripheral arterial occlusive disease
    Marquis, P
    DRUGS, 1998, 56 : 25 - 35
  • [3] Quality of life in patients with peripheral arterial occlusive disease
    Grigoriadou, M
    Petraki, M
    Ifanti, G
    Diamantopoulos, EJ
    13TH CONGRESS OF THE EUROPEAN CHAPTER OF THE INTERNATIONAL UNION OF ANGIOLOGY, 1999, : 173 - 176
  • [4] ASSESSMENT OF QUALITY-OF-LIFE OF PATIENTS WITH SEVERE ISCHEMIA AS A RESULT OF INFRAINGUINAL ARTERIAL OCCLUSIVE DISEASE
    ALBERS, M
    FRATEZI, AC
    DELUCCIA, N
    JOURNAL OF VASCULAR SURGERY, 1992, 16 (01) : 54 - 59
  • [5] Development of a disease-specific instrument for the assessment of quality of life in patients with peripheral arterial occlusive disease
    Bullinger, M
    Cachovan, M
    Creutzig, A
    Diehm, C
    Gruss, J
    Heidrich, H
    Kirchberger, I
    Loeprecht, H
    Rogatti, W
    VASA-JOURNAL OF VASCULAR DISEASES, 1996, 25 (01): : 32 - 47
  • [6] Quality of life assessment in peripheral arterial disease
    Hiatt, WR
    ATHEROSCLEROSIS, 1997, 131 : S35 - S36
  • [7] Quality of life after endovascular interventions for peripheral arterial occlusive disease
    Müller-Wille R.
    Wohlgemuth W.A.
    Gefässchirurgie, 2017, 22 (3) : 165 - 168
  • [8] PERIPHERAL ARTERIAL OCCLUSIVE DISEASE - MODERN THERAPEUTIC PRINCIPLES
    HACH, W
    HACH, V
    MUNCHENER MEDIZINISCHE WOCHENSCHRIFT, 1982, 124 (10): : 234 - 238
  • [9] QUALITY-OF-LIFE ASSESSMENT IN THERAPEUTIC TRIALS - RATIONALE FOR AND PRESENTATION OF A MORE APPROPRIATE INSTRUMENT
    GERIN, P
    DAZORD, A
    BOISSEL, J
    CHIFFLET, R
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1992, 6 (06) : 263 - 276
  • [10] Quality-of-life and walking impairment in peripheral arterial disease in the arterial diseases multiple intervention trial
    Hirsch, AT
    Garg, R
    Elam, JT
    Shindler, DM
    Pettinger, MB
    Wilt, TJ
    CIRCULATION, 1996, 94 (08) : 1013 - 1013